Skip to main content
. 2022 Jul 6;10(7):e004616. doi: 10.1136/jitc-2022-004616

Figure 1.

Figure 1

Inhibition of SCD1 enhances antitumor immune responses. C57BL/6 mice bearing MC38 or MCA205 tumors and Balb/c mice bearing CT26 or 4T1 tumors were treated with a SCD inhibitor (SCDinh) or with vehicle only (mock). (A) Ratios of palmitoleic acid / palmitic acid and oleic acid / stearic acid in the tumor, draining lymph nodes (dLN) and sera in C57BL/6-MC38 and Balb/c-CT26 model. (B) Tumor-growth curves in mean tumor volumes (mm3 ± standard deviation (SD); n=5) in four models. (C) Mean tumor volumes (mm3 ± SD; n=5) in MC38 tumor-bearing C57BL/6 mice that received a CD8-depleting or an isotype-matched monoclonal antibody. (D) Tumor‐infiltrating CD8+ T cells and irradiated syngeneic splenocytes cocultured and restimulated with gp70 peptide or β-gal peptide (negative control). In vivo tumor antigen‐specific T‐cell induction from tumor (TIL) and dLN evaluated by IFN-γ release assays in C57BL/6-MC38 (left panel) and in C57BL/6-MCA205 (right panel) models (means ± SD; n=3). (E) Percentages of gp70-specific CD8+ T cells in Balb/c-CT26 tumors analyzed by flow cytometry. Representative gp70-tetramer staining of CD8+ T cells in each group (left panel) and for all individuals (right panel) (n=5). *P<0.05, **P<0.01. Dep, depleted.